The Impact of Anticoagulation in Patients With Isolated Cancer‐Associated Splanchnic Vein Thrombosis: A Dual‐Center Cohort Study
Open Access
- 27 March 2026
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1379-1387
Abstract
Data to guide management of isolated bland cancer‐associated splanchnic vein thrombosis (CA‐SpVT) are limited. We aimed to assess the role of anticoagulation (AC) and bleeding and thrombosis in patients with CA‐SpVT. We conducted a dual‐center retrospective cohort study of adults with incident, isolated, bland CA‐SpVT from 2011 to 2020. The primary outcome was major bleeding (MB); other outcomes included usual‐site venous thromboembolism (VTE) recurrence and progression/recanalization of CA‐SpVT. Time‐to‐event outcomes were analyzed with weighted Cox models adjusting for cancer type, stage, SpVT location, and whether symptomatic. For SpVT recanalization/progression, differences were estimated using weighted average treatment effects (ATEs). After excluding tumor thrombus, we included 437 patients with notable characteristics of median age 60 years, portal vein thrombosis (81.2%), and underlying hepatocellular cancer (35.9%). Of these, 29.5% received therapeutic AC. At 6 months, there were 11.9% MB and 6.4% incident usual‐site VTE events. Among 308 patients with follow‐up imaging, the 1‐year thrombus progression rate was 19.8% and thrombus recanalization was 28.6%. In the adjusted analysis, there were numerically higher rates of MB with AC (adjusted hazard ratio [aHR] 1.93, 95% confidence interval [CI] 0.97–3.87) and no significant difference in the incidence of VTE (aHR 1.41, 95% CI 0.56–3.51). AC was associated with significantly higher likelihood of venous recanalization (ATE +24% 95% CI 13%–35%) and significantly lower likelihood of thrombus progression (ATE –14% 95% CI –23% to −5%). In patients with isolated bland CA‐SpVT, AC was associated with thrombus recanalization and limited thrombus progression; effects were offset by a potentially higher risk of MB.Keywords
This publication has 46 references indexed in Scilit:
- Management and outcomes in patients with tumor thrombus: a retrospective cohort studyJournal of Thrombosis and Haemostasis, 2024
- Anticoagulation for splanchnic vein thrombosis in myeloproliferative neoplasms: a systematic review and meta-analysisJournal of Thrombosis and Haemostasis, 2024
- Natural history of cancer-associated splanchnic vein thrombosisJournal of Thrombosis and Haemostasis, 2024
- Risk of recurrent cancer-associated venous thromboembolism: A Danish nationwide cohort studyInternational Journal of Cardiology, 2023
- Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapyResearch and Practice in Thrombosis and Haemostasis, 2023
- Developing and optimizing a computable phenotype for incident venous thromboembolism in a longitudinal cohort of patients with cancerResearch and Practice in Thrombosis and Haemostasis, 2022
- More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCCHepatology Communications, 2021
- Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysisStatistics in Medicine, 2016
- The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experimentsStatistics in Medicine, 2013
- Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapiesHepatology, 2012